JP2016512494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512494A5 JP2016512494A5 JP2015562509A JP2015562509A JP2016512494A5 JP 2016512494 A5 JP2016512494 A5 JP 2016512494A5 JP 2015562509 A JP2015562509 A JP 2015562509A JP 2015562509 A JP2015562509 A JP 2015562509A JP 2016512494 A5 JP2016512494 A5 JP 2016512494A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- pharmaceutically acceptable
- ester
- acceptable salt
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 58
- 150000003839 salts Chemical class 0.000 claims 27
- 239000011780 sodium chloride Substances 0.000 claims 27
- 150000002148 esters Chemical class 0.000 claims 26
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 239000000843 powder Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 11
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 11
- 239000000969 carrier Substances 0.000 claims 10
- QZZUEBNBZAPZLX-QFIPXVFZSA-N Indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 9
- 229960001664 Mometasone Drugs 0.000 claims 9
- 229940005644 glycopyrronium Drugs 0.000 claims 9
- 229960004078 indacaterol Drugs 0.000 claims 9
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 229940112141 Dry Powder Inhaler Drugs 0.000 claims 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 3
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- HZHXFIDENGBQFQ-FTBISJDPSA-N acetic acid;5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one Chemical compound CC(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 HZHXFIDENGBQFQ-FTBISJDPSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive Effects 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000002209 hydrophobic Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- 230000002685 pulmonary Effects 0.000 claims 2
- 230000000241 respiratory Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2S)-N-[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000003434 inspiratory Effects 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784842P | 2013-03-14 | 2013-03-14 | |
| US61/784,842 | 2013-03-14 | ||
| PCT/IB2014/059739 WO2014141135A1 (en) | 2013-03-14 | 2014-03-13 | Respirable agglomerates of porous carrier particles and micronized drug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512494A JP2016512494A (ja) | 2016-04-28 |
| JP2016512494A5 true JP2016512494A5 (de) | 2017-04-13 |
| JP6374414B2 JP6374414B2 (ja) | 2018-08-15 |
Family
ID=50478894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562509A Active JP6374414B2 (ja) | 2013-03-14 | 2014-03-13 | 多孔質担体粒子および微粒子化薬物の呼吸用凝集体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9452139B2 (de) |
| EP (1) | EP2968570A1 (de) |
| JP (1) | JP6374414B2 (de) |
| KR (1) | KR20150129716A (de) |
| CN (1) | CN105188757B (de) |
| AU (2) | AU2014229265A1 (de) |
| BR (1) | BR112015021814A2 (de) |
| CA (1) | CA2905615A1 (de) |
| CL (1) | CL2015002632A1 (de) |
| EA (1) | EA201591729A1 (de) |
| GT (1) | GT201500295A (de) |
| HK (1) | HK1212616A1 (de) |
| IL (1) | IL240963A (de) |
| MA (1) | MA38397A1 (de) |
| MX (1) | MX2015012814A (de) |
| PE (1) | PE20151655A1 (de) |
| PH (1) | PH12015501882A1 (de) |
| SA (1) | SA515361055B1 (de) |
| SG (1) | SG11201506397QA (de) |
| TN (1) | TN2015000395A1 (de) |
| WO (1) | WO2014141135A1 (de) |
| ZA (1) | ZA201505768B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2624554T3 (es) | 2005-12-28 | 2017-07-14 | Vertex Pharmaceuticals Incorporated | Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| EP3045452A1 (de) | 2010-04-22 | 2016-07-20 | Vertex Pharmaceuticals Inc. | Verfahren zur herstellung von cycloalkylcarboxamid-indol-verbindungen |
| CA2898682A1 (en) * | 2013-01-31 | 2014-08-07 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| JP2017508776A (ja) * | 2014-03-27 | 2017-03-30 | ノバルティス アーゲー | 医薬品有効成分吸入用の噴霧乾燥した水中油中固体分散体 |
| HUE062736T2 (hu) | 2014-04-15 | 2023-12-28 | Vertex Pharma | Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére |
| CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
| US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
| EP3335699A1 (de) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag-formulierung in flüssigfestem system |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| US20200375945A1 (en) * | 2019-06-03 | 2020-12-03 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| JP2022544398A (ja) * | 2019-08-15 | 2022-10-18 | アボット・ラボラトリーズ | 微粒子化を使用する栄養粉末製造プロセスおよび粉末組成物 |
| KR20220167315A (ko) * | 2020-04-13 | 2022-12-20 | 유니버지퇴트슈피탈 바젤 | Lsd 용량 확인 |
| CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
| TW202237102A (zh) * | 2020-12-11 | 2022-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 用於肺部遞送的藥物組合物 |
| CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| SK279642B6 (sk) | 1991-06-26 | 1999-01-11 | Schering Corporation | Inhalátor na práškové látky |
| AU683036B2 (en) | 1992-12-18 | 1997-10-30 | Merck Sharp & Dohme Corp. | Inhaler for powdered medications |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| CZ289029B6 (cs) | 1994-09-21 | 2001-10-17 | Inhale Therapeutic Systems | Způsob aerosolizace práąku, zejména práąkového léku a zařízení k provádění tohoto způsobu |
| NZ324374A (en) | 1996-01-03 | 1999-06-29 | Glaxo Group Ltd | Inhalation device |
| DE69712324T2 (de) | 1996-02-21 | 2002-08-29 | Schering Corp., Kenilworth | Inhalator für pulverartiges medikament |
| DK0937041T3 (da) | 1996-11-11 | 2003-08-11 | Christian R Noe | Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| EP1131059B1 (de) | 1998-11-13 | 2003-03-05 | Jago Research Ag | Trockenpulver zur inhalation |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| DK1181069T3 (da) | 1999-05-28 | 2006-10-09 | Nektar Therapeutics | Apparat og fremgangsmåde til aerosolisering af en pulverformig pharmaceutisk formulering |
| US20010029947A1 (en) | 1999-12-17 | 2001-10-18 | Steve Paboojian | Receptacles to facilitate the extraction of powders |
| US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| ES2525087T5 (es) | 2000-05-10 | 2018-06-28 | Novartis Ag | Polvos basados en fosfolípidos para administración de fármacos |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| JP2006511617A (ja) | 2002-12-13 | 2006-04-06 | アダーギット | 製薬用多孔質粒子 |
| PT1610850E (pt) | 2003-04-09 | 2012-06-15 | Novartis Ag | Dispositivo para gerar um aerossol com protecção da entrada de ar |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| CN100589849C (zh) | 2004-02-24 | 2010-02-17 | 微计量技术有限公司 | 基于合成射流的药物输送方法和装置 |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| MX2008016542A (es) | 2006-06-30 | 2009-01-19 | Novartis Ag | Derivados de quinolina y sus composiciones farmaceuticas. |
| RU2463085C2 (ru) | 2006-10-25 | 2012-10-10 | Новартис Аг | Аппарат для распыления порошка, способ его изготовления и применения и его компоненты |
| MX2010012452A (es) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Suministro pulmonar de una fluoro-quinolona. |
| MX344153B (es) | 2009-04-09 | 2016-12-07 | Novartis Ag | Proceso para la preparación de sales de pirrolidinio. |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| CN104257610A (zh) | 2010-04-01 | 2015-01-07 | 奇斯药制品公司 | 用于制备可吸入干粉所用的载体颗粒的方法 |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Application Discontinuation
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/de not_active Withdrawn
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en active Application Filing
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-01-20 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512494A5 (de) | ||
| CN105188757B (zh) | 多孔载体颗粒和微粒化药物的可吸入团聚物 | |
| RU2015146871A (ru) | Сухие порошки с тиотропием | |
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| JP2016515576A5 (de) | ||
| JP2017509684A5 (de) | ||
| RU2010141331A (ru) | Новая доза и препаративная форма | |
| RU2013140706A (ru) | Сухие порошковые композиции в виде частиц, которые содержат два или более активных ингредиента, для лечения обструктивных или воспалительных заболеваний дыхательных путей | |
| RU2013118453A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| JP2017502064A5 (de) | ||
| RU2014140674A (ru) | Новая дозировка и препаративная форма | |
| JPWO2019207061A5 (de) | ||
| JP2019534270A5 (de) | ||
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| JP2016534142A5 (de) | ||
| IL167009A (en) | Dry powder formoterol or its derivatives for inhalation | |
| JP2019501876A5 (de) | ||
| JP2014224147A5 (de) | ||
| PT1545634E (pt) | Método para preparar composições de pó seco para inalação | |
| RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
| JP2015519356A5 (de) | ||
| JP2018537453A5 (de) | ||
| RU2015143927A (ru) | Деаморфизация высушенных распылением составов посредством смешивания распылением | |
| US9682038B2 (en) | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy | |
| JP2016506946A (ja) | 吸入療法用の多成分結晶粒子 |